OBJECTIVES: Chronic pulmonary aspergillosis (CPA) is an emerging complication after lobectomy for lung cancer. This retrospective study aimed to determine the incidence, main risk factors and clinical features of postoperative CPA in lung cancer patients.
INTRODUCTION
Lung cancer is responsible for a high number of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) accounts for 80-85% of all lung cancers [1] . In recent years, although the postoperative outcomes for NSCLC have improved, the prognosis remains poor because of late respiratory failure, comorbid cardiovascular and respiratory conditions and perioperative acute cardiorespiratory failure in patients with existing lung diseases, such as chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) [2] [3] [4] .
Lung cancer occurs at a high incidence among patients with pulmonary aspergillosis [5] . Moreover, lung cancer-specific aspergillosis is also detected in cavitated lung cancer, and on postoperative bronchial stumps [6, 7] . Pulmonary aspergillosis in its general form includes invasive pulmonary aspergillosis (IPA), chronic pulmonary aspergillosis (CPA), simple pulmonary aspergilloma (SPA) and allergic bronchopulmonary aspergillosis [8] . CPA, described by Denning et al., is considered a comprehensive concept that maintains a transitional form between IPA and SPA, including chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, semi-IPA, chronic necrotizing pulmonary aspergillosis and chronic progressive pulmonary aspergillosis [9] [10] [11] [12] . In addition to lung cancer-specific aspergillosis, CPA is also suggested to be associated with previously treated lung cancer and thoracic surgery as well as cavitary or cystic lung diseases, such as pulmonary tuberculosis, COPD or bullae with or without emphysema [13] . Furthermore, Matsuura et al. reported that aspergillosis develops after lung cancer resection in 11 of 19 cases of lung cancer complicated by aspergillosis [14] . However, no studies have investigated the preoperative risk factors, postoperative incidence and postoperative clinical characteristics of CPA among patients undergoing surgery for lung cancer.
This study aimed to determine the incidence of postoperative CPA among lung cancer patients who underwent lobectomy. Subsequently, the characteristics of patients with and without CPA at the time of surgery were retrospectively compared to evaluate whether the patients' backgrounds, pulmonary comorbidities such as COPD and ILD or lung cancer situations are a risk factor for CPA. Furthermore, the characteristics of post-lobectomy CPA were also attempted to be clarified in this study.
MATERIALS AND METHODS

Study population
The medical files of all lung cancer patients undergoing elective ablative surgery at the National Hospital Organization Tokyo National Hospital between January 2000 and December 2009 were retrospectively reviewed. The inclusion criteria were as follows: (i) no history of thoracic surgery prior to lung cancer treatment; (ii) no complicating aspergillosis evident on preoperative computed tomography (CT) images and pathological images of resected tissue and (iii) standard lobectomy procedure for lung cancer. Our institutional review board approved the study (obtained on 3 March 2014; approval number: 2014010), and informed consent was considered unnecessary given the retrospective design of this study. This study was conducted in accordance with the Declaration of Helsinki.
The identified patients were separated into two groups based on their postoperative CPA status: those with CPA (the CPA group) and those without CPA (the non-CPA group). The diagnosis of CPA required all of the following criteria, as proposed by Denning et al., to be met: (i) chronic pulmonary or systemic symptoms; (ii) cavitary pulmonary lesion(s) with evidence of paracavitary infiltrates; (iii) either a positive serum Aspergillus precipitin test result or isolation of Aspergillus spp.; (iv) elevated levels of inflammatory markers; (v) exclusion of other pulmonary pathogens; (vi) not immunocompromised [9] .
Data collection
In our hospital, an independent lung cancer database has been compiled from medical records. The medical records were reviewed, and preoperative details of the onset of lung cancer, its treatment and its treatment outcomes were collected for comparison of the characteristics between the non-CPA and CPA groups. The following preoperative and follow-up clinicopathological findings were collected: baseline characteristics, pathological findings of the resected lung cancer specimens, laboratory data and radiographic findings. At our hospital, the patients were followed in principle as outpatients for a minimum of 5 years after surgery, with or without input from the patient's family doctor; patients who were experiencing pulmonary comorbidities or who wanted additional follow-up were seen beyond this standard period.
Incidence rate and risk factors
The cumulative incidence function was used, with the number of deaths between lobectomy and CPA occurrence as a competing risk, to determine the incidence and risk factors of CPA following lobectomy for lung cancer [15] . Specific candidate risk factors for the development of postoperative CPA were identified, including baseline preoperative characteristics (e.g. sex, age and smoking history) and preoperative comorbidities (diabetes mellitus as systemic comorbidities and COPD, ILD and pulmonary tuberculosis as pulmonary comorbidities). Diabetes mellitus was diagnosed based on glycosylated haemoglobin values ≥6.5%. COPD was diagnosed based on a preoperative forced expiratory volume in 1 s/forced vital capacity (FEV 1 /FVC) ratio of <70%. ILD was diagnosed by the presence of obvious bilateral fibrotic changes in the lower lung fields on preoperative CT. Active pulmonary tuberculosis was identified at the time of surgery by sputum positive for Mycobacterium tuberculosis, whereas inactive pulmonary tuberculosis was determined by a history of past tuberculosis treatment.
The following parameters were also included as potential risk factors of CPA: lung cancer characteristics (hilar/peripheral), location (left/right lung, upper/middle/lower lobe), histological subtype, tumour diameter, pathological stage and resection extent (single/ double lobectomy, combined chest wall resection). Using our medical records, the positive rates of the selected factors were investigated in the CPA and non-CPA groups.
Statistical analysis
All quantitative data were expressed as number of cases and percentages. The preoperative features were compared between the non-CPA and CPA groups. The duration between surgery and the incidence of CPA was mainly analysed, with death from any cause as a competing risk. Cumulative incidence was assessed to account for competing risks. Both crude hazard ratios and adjusted hazard ratios were estimated using a proportional hazards model extended to cases of competing risk [16] . In a multivariable analysis, effective factors were selected using a backward-elimination variable selection method at a significance level of P < 0.05. Mortality from CPA was estimated using the Kaplan-Meier method. All statistical analyses were conducted using the R Statistical Software Package 'cmprsk' (R Project for Statistical Computing; https://www.r-project.org).
RESULTS
Patient characteristics
The data for 475 lung cancer patients treated by lobectomy were included. Their characteristics are summarized in Table 1 . The patients were predominantly male (68%) and smokers (65%) and had a median age of 68 years. The most common comorbidities were diabetes (17%), followed by COPD (12%), ILD (5%) and pulmonary tuberculosis (4%; 2 active and 18 inactive). None of the patients were infected with the human immunodeficiency virus. Most cases of lung cancer were peripheral (92%), Stage I (61%) and adenocarcinomas (67%), typically affecting the right lung (58%) and upper lobes (57%). Accordingly, the predominant surgery was single lobectomy (97%), with no combined thoracic wall resection (91%).
Chronic pulmonary aspergillosis incidence
Of the 475 patients, 17 (3.6%) developed postoperative CPA. Figure 1 shows the incidence of CPA calculated using the cumulative incidence function, with the number of deaths as a competing risk. After surgery, the incidence rate of CPA was 2.3% [95% confidence interval (CI), 0.8-3.8%] at 5 years and 7.9% (95% CI, 3.0-13.0%) at 10 years, indicating an increase in the CPA comorbidity rate over time.
Risk factors of postsurgical chronic pulmonary aspergillosis
The preoperative clinical characteristics of the CPA and non-CPA groups are compared in Table 2 . Among the 17 patients of the CPA group in which the median age was 66 years [interquartile range (IQR): 60-75], 16 were men and 16 were smokers. Most patients in the CPA group (71%) presented with pulmonary comorbidities, namely COPD (35%), ILD (24%) or pulmonary tuberculosis (12%). In this group, lung cancer was generally Stage I/II, peripheral and predominantly in the right lung and upper lobe. The univariable analysis revealed several distinctions between the non-CPA and CPA groups. The proportions of male patients (P = 0.007), smokers (P = 0.002) and those with COPD (P = 0.008) and ILD comorbidities (P = 0.009) were significantly higher in the CPA group than in the non-CPA group. However, there was no difference in terms of age, the extent of resection or the presence/absence of diabetes mellitus, pulmonary tuberculosis and the characteristics of the lung cancer. Only one of the 17 patients with CPA had both COPD and ILD comorbidities.
The multivariable analysis identified COPD (P = 0.0019) and interstitial pneumonia (P = 0.0003) as significant risk factors of postoperative CPA (Table 3) .
Clinical features of postoperative chronic pulmonary aspergillosis
The clinical characteristics and treatment outcomes of the 17 CPA patients are presented in Table 4 . In all patients, CPA developed in the residual lung lobe on the side where surgery was performed. After lobectomy, air-space expansion in the residual lobe gradually occurred followed by subsequent infiltration, and a cavity was observed on the radiographs (Fig. 2 provides representative images in a single patient). The median duration between resection and CPA occurrence was 58 months (IQR: 25-93) and 8 patients (47%) developed CPA ≥5 years after the surgery. In 6 patients, lung cancer recurrence was observed before the emergence of CPA. All 17 patients were positive for Aspergillus infection by Denning's criteria at the time of CPA diagnosis, as detected either in serum precipitins (88%) or sputum cultures (41%) [9] . In the 7 patients diagnosed using sputum cultures, the species was identified as Aspergillus fumigatus (5/7) or A. niger (2/7). Chemotherapy was administered to 2 patients with multiple pulmonary metastases and radiation therapy to 2 patients with brain metastases, and partial resection was performed in 1 patient with a single pulmonary metastasis in the opposite lung; radiation therapy was administered to the remaining patient with a single pulmonary metastasis in the lobectomy-side lung because the patient selected radiotherapy because of his poor physical condition. Preoperative CT showed distinct inactive tuberculous shadows in 2 of the 17 patients. One of them had lung cancer with inactive tuberculous shadows within the same upper lobe, whereas the other had inactive tuberculous shadows in the upper lobe and lung cancer in the lower lobe. Therefore, only 2 patients (1 post-radiotherapy lesion and 1 inactive tuberculous lesion) may have CPA precursor lesions in the residual lobes.
Antifungal treatment was generally initiated with itraconazole (oral = 10; intravenous = 5), whereas one patient received voriconazole and the last patient received micafungin. In 4 patients, itraconazole was replaced by voriconazole early during the treatment because of insufficient efficacy. In addition, 1 patient was treated with itraconazole and pneumonectomy of the residual lung after lobectomy. The evaluation of CPA treatment efficacy was based on the radiographic findings alone because the clinical findings were influenced by lung cancer recurrence or postoperative cardiorespiratory problems. The overall treatment response rate at 6 months was 35% (6/17 patients; 5 patients improved with drug therapy alone, and 1 improved with the combination of drug therapy and pneumonectomy), and the radiographic findings at 6 months revealed stable CPA in 4 patients. However, 6 of the remaining 7 patients who did not respond to antifungal treatment died within 6 months either because of CPA (4 patients), cancer (1 patient) and unrelated causes (1 patient). The overall survival curve showed in Fig. 3 that the 1-year survival rate was 47% (follow-up periods, IQR: 3-78 months), and 5 of the total of 11 deaths were due to CPA.
DISCUSSION
CPA as a sequel to pulmonary tuberculosis is well known, and the 5-year prevalence rates of CPA vary geographically, in the range of 0.4-51, and 2.8% in Japan [17] . This study demonstrates, for the first time, that the 5-year incidence rate of CPA as a late sequela in patients undergoing lobectomy for lung cancer was 2.3%, comparable with CPA frequency after pulmonary tuberculosis. Furthermore, in selected cases who continued to visit our hospital over 5 years, the 10-year incidence rate reached 7.9%. These findings suggest that CPA is a critically important late post-lobectomy infection among patients treated for lung cancer.
Postoperative comorbidities, such as prolonged air leaks, chylothorax, postoperative haemorrhage, recurrent nerve injury, arrhythmia, pulmonary embolism, empyema, pneumonia and wound infection, are known to occur after lung cancer surgery [18] . However, the actual conditions that predispose one to a sequel have not been discussed because it is difficult to determine causal relationships between surgery and the development of symptoms a long time after surgery.
Matsuura et al. reported that 10 of 11 lung cancer patients develop pulmonary aspergillosis in the residual lung on the surgical side [14] . Likewise, all 17 patients in the present study developed CPA in the residual lung on the side of the lobectomy. Tanaka et al. also reported the presence of fibrobullous changes in 39 residual lobes from 1321 patients ( 3%) who underwent lobectomy for primary lung cancer, with the incidence rate increasing to 5.6% for the patients who survived ≥5 years [19] . Interestingly, fibrobullous changes are not observed in the patients who underwent pneumonectomy, segmentectomy or wedge resection. Tanaka et al. also noted that 21 of 39 patients with fibrobullous changes are infected with non-tuberculous Mycobacterium spp., Aspergillus spp. or methicillin-resistant Staphylococcus aureus, with 10 patients dying from infection or respiratory failure rather than from lung cancer recurrence. The authors therefore concluded that fibrobullous changes are a critical late complication after lobectomy for lung cancer. The term 'fibrobullous changes' may be a synonym of airspace expansion of the residual lobe with superimposed infections including CPA and their precursor lesions. Following this logic, CPA can be considered a sequel to lung cancer that is attributable to lobectomy.
In the present study, the occurrence of CPA was not associated with age or the clinical characteristics of lung cancer. Instead, preexisting comorbid COPD or ILD was found as a critical risk factor for postoperative CPA. Lung re-expansion is known to occur in the residual lobes after lobectomy [20] . Patients with lung cancer and comorbid COPD may be prone to developing CPA because of further emphysema expansion influenced by re-expansion of the residual lobe after lobectomy. Conversely, case reports of idiopathic pulmonary fibrosis, a representative ILD, are only occasionally observed as a CPA-related disease [21] . Despite this, idiopathic pulmonary fibrosis, which should be considered, is known to cause honeycomb cysts that can expand slowly after a long disease course [22] . It may therefore be reasonable to assume that residual lung expansion after lobectomy promotes the early occurrence of honeycomb cyst formation and expansion in patients with lung cancer and comorbid ILD, thereby increasing the likelihood of CPA developing in the expanded air space.
In the present study, 16 of the 17 CPA patients had a positive smoking history. Although smoking history was not a significant risk factor for CPA in the multivariable analysis, it was a significant risk factor in the univariable analysis. In the report by Tanaka et al., 35 of 39 patients with fibrobullous changes had a history of heavy smoking [19] . Thus, the development of COPD or ILD due to smoking-induced lung injury may be an underlying cause of CPA. CPA, which tends to affect middle-aged patients manifesting fever, malaise, fatigue, weight loss and respiratory symptoms, is a progressive disease causing destruction of the lung. The CPA condition is associated with high morbidity and mortality and, therefore, long-term antifungal agents, such as itraconazole or voriconazole, are typically used to treat CPA, with response rates ranging from 50 to 80% in the general population, and surgery also can be useful for treating CPA [23] . Moreover, the mortality rate associated with CPA in the general population has been reported to be 51% during a median follow-up period of 15 months and 50% during a mean follow-up period of 28.7 months [24, 25] . However, the response rate to itraconazole and voriconazole was low among the lung cancer patients with CPA in our study (35%). Four patients died from CPA within 6 months of diagnosis; the 1-year survival rate was 47%, and 5 of the total of 11 deaths were due to CPA, indicating a poor prognosis for CPA after lobectomy for lung cancer. This finding may be explained by the impact of cardiorespiratory insufficiency due to comorbidities or lung cancer recurrence after lobectomy. Another possible reason is that pneumonectomy for additional surgical resection of the CPA is refused by patients because the surgery may be a heavy burden for them.
In this study, CPA occurrence may have influenced the poor prognosis in resected lung cancer patients particularly with COPD or ILD. However, this influence is believed to be marginal because approximately half of the patients developed CPA >5 years after surgery.
This study presents some limitations that are inherent to the retrospective design and to CPA itself, including the limited number of CPA patients and limited data available in the medical records. There was also an imbalance regarding comparison between CPA (n = 17) and non-CPA (n = 458) patients. In addition, patients who continued to visit our outpatient department for >5 years after lobectomy were more likely to have pulmonary diseases, such as COPD and ILD, so that the 10-year incidence of CPA is limited and is not applicable to all lobectomy patients. Because of this bias, 10-year incidence of the present data may not be sufficient for CPA occurrence after lobectomy in lung cancer patients. However, the present data may support a significant impact of CPA occurrence on the clinical practice of follow-up after lung cancer surgery. Further prospective investigations may be required to identify important risk factors for CPA.
CONCLUSION
CPA seems to be a common sequel to lobectomy for lung cancer as well as a sequel to pulmonary tuberculosis in Japan. Given that CPA cases show high mortality, it may be essential that efforts be made to diagnose CPA, especially in patients with comorbid COPD or ILD. This can be done by ensuring adequate follow-up with several examinations for Aspergillus species and radiological imaging of the residual lung lobe by surgeons together with pulmonologists.
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